Work to progress this appraisal is continuing. Following the loss of exclusivity for Revlimid (branded lenalidomide), NHS England will shortly confirm the current NHS price of lenalidomide that is to be included in the economic modelling in this appraisal. We will provide a further update by 30 September 2022.